Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 5/2023

16.08.2023

Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices

verfasst von: Sumeet Vaikunth, Swethika Sundaravel, Joshua Saef, Juan Ortega-Legaspi

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This paper reviews the latest literature on the growing field of heart failure in the adult congenital heart disease population.

Recent Findings

After highlighting the increasing prevalence and a few of the unique potential causes, including the concept of early senescence, this review begins with novel medical management strategies such as the angiotensin II receptor blocker and neprilysin inhibitors and sodium glucose cotransporter-2 inhibitors. Then, it addresses the latest applications of percutaneous techniques like implantable hemodynamic monitoring, transcatheter pulmonary and aortic valve replacement, and mitral clips. Cardiac resynchronization therapy and novel lymphatic system imaging and intervention are then described. Finally, the use of mechanical support devices, temporary and durable, is discussed as well as heart and combined heart and liver transplantation.

Summary

There have been recent exciting advances in the strategies used to manage adult congenital heart disease patients with heart failure. As this population continues to grow, it is likely we will see further rapid evolution in this field.
Literatur
1.
Norozi K, Wessel A, Alpers V, Arnhold JO, Geyer S, Zoege M, et al. Incidence and risk distribution of heart failure in adolescents and adults with congenital heart disease after cardiac surgery. Am J Cardiol. 2006;97(8):1238–43.PubMedCrossRef
2.
Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000;86(10):1111–6.PubMedCrossRef
3.
Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132(22):2118–25.PubMedCrossRef
4.
Christopher Y, Moore BM, Kotchetkova I, Cordina RL, Celermajer DS. Causes of death in a contemporary adult congenital heart disease cohort. Heart. 2018;104(20):1678.CrossRef
5.
Engelings CC, Helm PC, Abdul-Khaliq H, Asfour B, Bauer UMM, Baumgartner H, et al. Cause of death in adults with congenital heart disease — an analysis of the German National Register for Congenital Heart Defects. Int J Cardiol. 2016;211:31–6.PubMedCrossRef
6.
Burstein DS, Rossano JW, Griffis H, Zhang X, Fowler R, Frischertz B, et al. Greater admissions, mortality and cost of heart failure in adults with congenital heart disease. Heart. 2021;107(10):807–13.PubMedCrossRef
7.
Arnaert S, De Meester P, Troost E, Droogne W, Van Aelst L, Van Cleemput J, et al. Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors. ESC Heart Fail. 2021;8(4):2940–50.PubMedPubMedCentralCrossRef
8.
Fahed AC, Roberts AE, Mital S, Lakdawala NK. Heart failure in congenital heart disease. Heart Fail Clin. 2014;10(1):219–27.PubMedCrossRef
9.
Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016;133(8):770–801.PubMedCrossRef
10.
Moore JP, Marelli A, Burchill LJ, Chubb H, Roche SL, Cedars AM, et al. Management of heart failure with arrhythmia in adults with congenital heart disease. J Am Coll Cardiol. 2022;80(23):2224–38.PubMedCrossRef
11.•
Moons P, Marelli A. Born to age: when adult congenital heart disease converges with geroscience. JACC Adv. 2022;1(1):100012. This recent publication details how CHD patients have characteristics of early senescence, including shorted telomere length.CrossRef
12.
Wienecke LM, Cohen S, Bauersachs J, Mebazaa A, Chousterman BG. Immunity and inflammation: the neglected key players in congenital heart disease? Heart Fail Rev. 2022;27(5):1957–71.PubMedCrossRef
13.•
Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112(6):828–35. Though not a recent study, this evaluation of peak VO2 still remains an essential piece of knowledge that shows that peak VO2 in ACHD patients who are much younger is not different than peak VO2 in general cardiology patients presenting in heart failure in their 50s and 60s.PubMedCrossRef
14.
Miranda WR, Jain CC, Borlaug BA, Jaffe AS, Connolly HM, Burchill LJ, et al. Exercise capacity, NT-proBNP, and exercise hemodynamics in adults post-Fontan. J Am Coll Cardiol. 2023;81(16):1590–600.PubMedCrossRef
15.
Jain CC, Egbe AC, Reddy YNV, Connolly HM, Hagler DJ, Miranda WR. Role of exercise during invasive hemodynamic assessment in symptomatic adults with a systemic right ventricle. JACC Adv. 2022;1(2):100023.CrossRef
16.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18) https://​doi.​org/​10.​1161/​CIR.​0000000000001063​.
17.
Riesgo Gil F, Brida M. Response to letter regarding article ‘Heart failure in adults with congenital heart disease’. Int J Cardiol. 2022;367:26.PubMedCrossRef
18.
Andrade L, Ortega-Legaspi JM, Awh K, Fuller S, Patel B, Tobin L, et al. Diuretic use in the adult Fontan. Int J Cardiol Congenit Heart Dis. 2022;8:100387.CrossRef
19.
Yim DLS, Jones BO, Alexander PMA, d’Udekem Y, Cheung MMH. Effect of anti-heart failure therapy on diastolic function in children with single-ventricle circulations. Cardiol Young. 2015;25(7):1293–9.PubMedCrossRef
20.
Doughan ARK, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol. 2007;99(5):704–6.PubMedCrossRef
21.
Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol. 2007;114(2):241–6.PubMedCrossRef
22.
Bouallal R, Godart F, Francart C, Richard A, Foucher-Hossein C, Lions C. Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young. 2010;20(06):615–9.PubMedCrossRef
23.
Van Der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, et al. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127(3):322–30.PubMedCrossRef
24.
Tutarel O, Meyer GP, Bertram H, Wessel A, Schieffer B, Westhoff-Bleck M. Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right ventricle. Int J Cardiol. 2012;154(1):14–6.PubMedCrossRef
25.
Lester SJ, McElhinney DB, Viloria E, Reddy GP, Ryan E, Tworetzky W, et al. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol. 2001;88(11):1314–6.PubMedCrossRef
26.
Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. 2008;129(2):187–92.PubMedCrossRef
27.
Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. 2005;112(16):2411–6.PubMedCrossRef
28.
Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol. 2001;87(5):660–3. A11PubMedCrossRef
29.
Dos L, Pujadas S, Estruch M, Mas A, Ferreira-González I, Pijuan A, et al. Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. Int J Cardiol. 2013;168(6):5167–73.PubMedCrossRef
30.
Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(14):e801–13.PubMedCrossRef
31.
Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation. 1997;96(5):1507–12.PubMedCrossRef
32.
Wilson TG, Iyengar AJ, d’Udekem Y. The use and misuse of ACE inhibitors in patients with single ventricle physiology. Heart Lung Circ. 2016;25(3):229–36.PubMedCrossRef
33.
Appadurai V, Thoreau J, Malpas T, Nicolae M. Sacubitril/valsartan in adult congenital heart disease patients with chronic heart failure − a single centre case series and call for an international registry. Heart Lung Circ. 2020;29(1):137–41.PubMedCrossRef
34.
Lluri G, Lin J, Reardon L, Miner P, Whalen K, Aboulhosn J. Early experience with sacubitril/valsartan in adult patients with congenital heart disease. World J Pediatr Congenit Heart Surg. 2019;10(3):292–5.PubMedCrossRef
35.
Maurer SJ, Pujol Salvador C, Schiele S, Hager A, Ewert P, Tutarel O. Sacubitril/valsartan for heart failure in adults with complex congenital heart disease. Int J Cardiol. 2020;300:137–40.PubMedCrossRef
36.
Zandstra TE, Nederend M, Jongbloed MRM, Kiès P, Vliegen HW, Bouma BJ, et al. Sacubitril/valsartan in the treatment of systemic right ventricular failure. Heart. 2021;107(21):1725–30.PubMedCrossRef
37.
Yan L, Loh JK, Tan JL. Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease – experience from a tertiary centre in Singapore. Int J Cardiol Congenit Heart Dis. 2021;6:100268.CrossRef
38.••
Fusco F, Scognamiglio G, Merola A, Iannuzzi A, Palma M, Grimaldi N, et al. Safety and efficacy of sacubitril/valsartan in patients with a failing systemic right ventricle: a prospective single-center study. Circ Heart Fail. 2022:e009848. This single center prospective study of sacubitril/valsartan in 50 patients with systemic right ventricle is the first prospective trial to show improvement in functional class, 6 minute walk distance, fractional area change, global longitudinal strain, ventricular volume and ejection fraction.
39.
Appadurai V, Nicolae M, Aboulhosn J, Lluri G. The protocol and rationale for the efficacy and tolerability of sacubitril-valsartan in adult congenital heart disease patients with heart failure (ENTRUST ACHD HF) registry. Int J Cardiol Congenit Heart Dis. 2021;3:100096.CrossRef
40.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18) https://​doi.​org/​10.​1161/​CIR.​0000000000001063​.
41.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.PubMedCrossRef
42.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.PubMedCrossRef
43.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.PubMedCrossRef
44.
Egorova AD, Nederend M, Tops LF, Vliegen HW, Jongbloed MRM, Kiès P. The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail. 2022;9(3):2007–12.PubMedPubMedCentralCrossRef
45.
Newland DM, Law YM, Albers EL, Friedland-Little JM, Ahmed H, Kemna MS, et al. Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol. 2023;44(1):146–52.PubMedCrossRef
46.
Muneuchi J, Sugitani Y, Kobayashi M, Ezaki H, Yamada H, Watanabe M. Feasibility and safety of sodium glucose cotransporter-2 inhibitors in adults with heart failure after the Fontan procedure. Mocan M, editor. Case Rep Cardiol. 2022;2022:1–5.
47.
Saef J, Sundaravel S, Ortega-Legaspi J, Vaikunth S. Safety and treatment experience with sodium/glucose cotransporter-2 inhibitors (SGLT2i) in adult patients with congenital heart disease. J Card Fail. 2023;S1071-9164(23):00104–5.
48.
Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: from molecular mechanisms to potential clinical implications. Pharmacol Res. 2022;181:106261.PubMedCrossRef
49.
Gewillig M, Brown SC. The Fontan circulation after 45 years: update in physiology. Heart. 2016;102(14):1081–6.PubMedCrossRef
50.
Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123(11):1185–93.PubMedPubMedCentralCrossRef
51.
Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, et al. Results of the FUEL trial. Circulation. 2020;141(8):641–51.PubMedCrossRef
52.
Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation. 2014;130(23):2021–30.PubMedCrossRef
53.
Cedars AM, Saef J, Peterson LR, Coggan AR, Novak EL, Kemp D, et al. Effect of ambrisentan on exercise capacity in adult patients after the fontan procedure. Am J Cardiol. 2016;117(9):1524–32.PubMedCrossRef
54.
Clift P, Berger F, Sondergaard L, Antonova P, Disney P, Nicolarsen J, et al. The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial. Eur Heart J. 2022;43(Supplement_2):ehac544.1560.CrossRef
55.
Koyak Z, de Groot JR, Krimly A, Mackay TM, Bouma BJ, Silversides CK, et al. Cardiac resynchronization therapy in adults with congenital heart disease. Europace. 2018;20(2):315–22.PubMedCrossRef
56.
Yin Y, Dimopoulos K, Shimada E, Lascelles K, Griffiths S, Wong T, et al. Early and late effects of cardiac resynchronization therapy in adult congenital heart disease. JAHA. 2019;8(21):e012744.PubMedPubMedCentralCrossRef
57.
Leyva F, Zegard A, Qiu T, Bono J, Thorne S, Clift P, et al. Long-term outcomes of cardiac resynchronization therapy in adult congenital heart disease. Pacing Clin Electrophysiol. 2019;42(6):573–80.PubMedPubMedCentralCrossRef
58.••
Chubb H, Rosenthal DN, Almond CS, Ceresnak SR, Motonaga KS, Arunamata AA, et al. Impact of cardiac resynchronization therapy on heart transplant-free survival in pediatric and congenital heart disease patients. Circ Arrhythm Electrophysiol. 2020;13(4):e007925. This single center, propensity score-matched study is the first to show a transplant-free survival benefit to cardiac resynchronization therapy in congenital heart disease.PubMed
59.
Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Heart Rhythm. 2014;11(10):e102–65.PubMedCrossRef
60.
Kharbanda RK, Moore JP, Lloyd MS, Galotti R, Bogers AJJC, Taverne YJHJ, et al. Cardiac resynchronization therapy for adult patients with a failing systemic right ventricle: a multicenter study. JAHA. 2022;11(22):e025121.PubMedPubMedCentralCrossRef
61.
Rösner A, Khalapyan T, Dalen H, McElhinney DB, Friedberg MK, Lui GK. Classic-pattern dyssynchrony in adolescents and adults with a fontan circulation. J Am Soc Echocardiogr. 2018;31(2):211–9.PubMedCrossRef
62.
Rösner A, McElhinney DB, Diab SG, Friedberg MK, Lui GK. Classic-pattern dyssynchrony is associated with outcome in patients with Fontan circulation. J Am Soc Echocardiogr. 2022;35(5):513–22.PubMedCrossRef
63.
Bradley EA, Berman D, Daniels CJ. First implantable hemodynamic monitoring device placement in single ventricle Fontan anatomy: IHM Fontan. Cathet Cardiovasc Interv. 2016;88(2):248–52.CrossRef
64.
Bradley EA, Jassal A, Moore-Clingenpeel M, Abraham WT, Berman D, Daniels CJ. Ambulatory Fontan pressure monitoring: results from the implantable hemodynamic monitor Fontan feasibility cohort (IHM-FFC). Int J Cardiol. 2019;284:22–7.PubMedCrossRef
65.
Salavitabar A, Bradley EA, Chisolm JL, Hickey J, Boe BA, Armstrong AK, et al. Implantable pulmonary artery pressure monitoring device in patients with palliated congenital heart disease: technical considerations and procedural outcomes. Catheter Cardiovasc Interv. 2020;95(2):270–9.PubMedCrossRef
66.
Bokma JP, Geva T, Sleeper LA, Lee JH, Lu M, Sompolinsky T, et al. Improved outcomes after pulmonary valve replacement in repaired tetralogy of Fallot. J Am Coll Cardiol. 2023;81(21):2075–85.PubMedCrossRef
67.
Gartenberg AJ, Gillespie MJ, Glatz AC. Transcatheter approaches to pulmonary valve replacement in congenital heart disease: revolutionizing the management of RVOT dysfunction? Semin Thorac Cardiovasc Surg. 2022:S104306792200048X.
68.
Martin MH, Gruber PJ, Gray RG. Transcatheter neoaortic valve replacement utilizing the melody valve in hypoplastic left heart syndrome: transcatheter neoaortic valve replacement. Cathet Cardiovasc Interv. 2015;85(4):615–9.CrossRef
69.
Yeong M, Bedair R, Baumbach A, Caputo M, Manghat N, Turner M. First successful trans-catheter aortic-valve replacement for native aortic stenosis in atrio-pulmonary Fontan. Int J Cardiol. 2016;222:963–4.PubMedCrossRef
70.
Schneider HE, Gravenhorst V, Paul T, Jacobshagen C. Insufficiency of a Damus-Kaye-Stansel anastomosis in a Fontan patient: transfemoral implantation of an Edwards Sapien 3 valve. Catheter Cardiovasc Interv. 2018;91(2):292–5.PubMedCrossRef
71.
Lehner A, Herrmann FE, Mehilli J, Haas NA. Edwards Sapien 3 transcatheter aortic valve implantation for management of severe aortic regurgitation in a teenage patient with corrected atrioventricular septal defect and progressive left ventricular dysfunction. Catheter Cardiovasc Interv. 2019;93(4):E244–7.PubMedCrossRef
72.
Sinha S, Khan A, Qureshi AM, Suh W, Laks H, Aboulhosn J, et al. Application of transcatheter valves for aortic valve replacement in pediatric patients: a case series. Catheter Cardiovasc Interv. 2020;95(2):253–61.PubMedCrossRef
73.
Robertson DM, Boucek DM, Martin MH, Gray RG, Griffiths ER, Eckhauser AW, et al. Transcatheter and surgical aortic valve implantation in children, adolescents, and young adults with congenital heart disease. Am J Cardiol. 2022;177:128–36.PubMedCrossRef
74.
Franzen O, von Samson P, Dodge-Khatami A, Geffert G, Baldus S. Percutaneous edge-to-edge repair of tricuspid regurgitation in congenitally corrected transposition of the great arteries: repair of tricuspid regurgitation. Congenit Heart Dis. 2011;6(1):57–9.PubMedCrossRef
75.
van Melle JP, Schurer R, Willemsen M, Hoendermis ES, van den Heuvel AFM. Percutaneous tricuspid valve repair using MitraClip® for the treatment of severe tricuspid valve regurgitation in a patient with congenitally corrected transposition of the great arteries. Neth Heart J. 2016;24(11):696–7.PubMedPubMedCentralCrossRef
76.
Picard F, Tadros VX, Asgar AW. From tricuspid to double orifice morphology: percutaneous tricuspid regurgitation repair with the MitraClip device in congenitally corrected-transposition of great arteries. Catheter Cardiovasc Interv. 2017;90(3):432–6.PubMedCrossRef
77.
Alshawabkeh L, Mahmud E, Reeves R. Percutaneous mitral valve repair in adults with congenital heart disease: report of the first case-series. Catheter Cardiovasc Interv. 2021;97(3):542–8.PubMedCrossRef
78.
Gaydos SS, Capps CD, Judd RN, Rhodes JF, Steinberg DH, Katz MR, et al. Hemodynamic impact of MitraClip procedure for systemic tricuspid regurgitation in congenitally corrected transposition of great arteries: a case report. Cardiovasc Revasc Med. 2021;28:114–7.CrossRef
79.
Luedike P, Riebisch M, Weymann A, Ruhparwar A, Rassaf T, Mahabadi AA. Feasibility of a novel transcatheter valve repair system to treat tricuspid regurgitation in ccTGA. JACC Case Rep. 2021;3(6):893–6.PubMedPubMedCentralCrossRef
80.
Lewis A, Hakemi E, Lopez D, Cubeddu RJ. MitraClip repair of right-sided atrioventricular valve in a patient with congenitally corrected transposition of the great arteries: a case report. Krupickova S, Moreno-Ruiz LA, Puricelli F, Doolub G, Dhahit A, editors. Eur Heart J Case Rep. 2022;6(1):ytab479.PubMedCrossRef
81.
82.
Tan W, Calfon Press M, Lluri G, Aboulhosn J. Percutaneous edge-to-edge repair for common atrioventricular valve regurgitation in a patient with heterotaxy syndrome, single ventricle physiology, and unbalanced atrioventricular septal defect. Catheter Cardiovasc Interv. 2020;96(2):384–8.PubMedCrossRef
83.
Stys T, Gedela M, Gelster C, Stys A. MitraClip intervention for severe mitral regurgitation with residual mitral valve cleft in a patient with prior partial congenital AV canal defect repair. Euro Interv. 2019;14(17):1740–1.
84.
Russo MJ, Garg A, Okoh A, Chaudhary A, Hakeem A, Lee LY, et al. MitraClip Implantation in a Patient With Post-Surgical Repair of Primum Atrial Septal Defect and Residual Mitral Cleft. JACC: Case Reports. 2020;2(12):2027–9.
85.
Blusztein D, Moore P, Qasim A, Mantri N, Mahadevan VS. Transcatheter edge-to-edge repair of systemic tricuspid valve in extracardiac fontan circulation. JACC Case Rep. 2022;4(4):221–5.PubMedPubMedCentralCrossRef
86.
Haeffele CL, Lui GK, Peng L, Chan F, Sharma RP. First described mitral clip in an adult extracardiac Fontan patient: a case report. Moroni F, Voges I, Montalto C, Ahmed AS, Van den Eynde J, Mohan S, editors. Eur Heart J Case Rep. 2022;7(1):ytac479.PubMedPubMedCentralCrossRef
87.
88.
Tomasulo CE, Chen JM, Smith CL, Maeda K, Rome JJ, Dori Y. Lymphatic disorders and management in patients with congenital heart disease. Ann Thorac Surg. 2022;113(4):1101–11.PubMedCrossRef
89.
90.
Dori Y, Mazurek J, Birati E, Smith C. Ascites in animals with right heart failure: correlation with lymphatic dysfunction. JAHA. 2023;12(7):e026984.PubMedPubMedCentralCrossRef
91.
92.
Kops SA, White SC, Klewer SE, Andrews JG, Seckeler MD. ECMO in adults with congenital heart disease - analysis of a national discharge database. Int J Cardiol Congenit Heart Dis. 2022;8:100366.CrossRef
93.
O’Neil E, Riedl R, Rycus P, Dolgner S, Alexander P, Hickey E, et al. Extracorporeal membrane oxygenation support for adult congenital heart disease. J Am Coll Cardiol. 2022;79(9):570.CrossRef
94.
Kalavrouziotis G, Karunaratne A, Raja S, Ciotti G, Purohit M, Corno AF, et al. Intra-aortic balloon pumping in children undergoing cardiac surgery: an update of the Liverpool experience. J Thorac Cardiovasc Surg. 2006;131(6):1382–1382.e10.PubMedCrossRef
95.
Moran AM, Blume ED, Quinn R. Intra-aortic balloon pump use in the failing Fontan circulation. Congenit Heart Dis. 2008;3(1):60–2.PubMedCrossRef
96.
Moustafa A, Khan MS, Saad M, Siddiqui S, Eltahawy E. Impella support versus intra-aortic balloon pump in acute myocardial infarction complicated by cardiogenic shock: a meta-analysis. Cardiovasc Revasc Med. 2022;34:25–31.PubMedCrossRef
97.
Fishberger SB, Asnes JD, Rollinson NL, Cleman MW. Percutaneous right ventricular support during catheter ablation of intra-atrial reentrant tachycardia in an adult with a mustard baffle—a novel use of the Impella device. J Interv Card Electrophysiol. 2010;29(1):69–72.PubMedCrossRef
98.
Morray BH, Dimas VV, Lim S, Balzer DT, Parekh DR, Van Mieghem NM, et al. Circulatory support using the impella device in Fontan patients with systemic ventricular dysfunction: a multicenter experience. Cathet Cardio Interv. 2017;90(1):118–23.CrossRef
99.
Hendriks A, De Vries L, Witsenburg M, Yap SC, Van Mieghem N, Szili-Torok T. Percutaneous ventricular assist device for circulatory support during ablation of atrial tachycardias in patients with Fontan circulation. Rev Esp Cardiol. 2018;71(6):493–5.PubMedCrossRef
100.
Wittwer ED, Pulido JN, Gillespie SM, Cetta F, Dearani JA. Left main coronary artery compression following melody pulmonary valve implantation: use of impella support as rescue therapy and perioperative challenges with ECMO. Case Rep Crit Care. 2014;2014:1–3.CrossRef
101.••
Broda CR, Frankel WC, Nair AP, Dreyer WJ, Tunuguntla HP, Frazier OH, et al. Continuous-flow ventricular assist device support in adult congenital heart disease: a 15-year, multicenter experience of temporary and durable support. ASAIO J. 2022; https://​doi.​org/​10.​1097/​MAT.​0000000000001853​. This single center case series from Texas Children’s Hospital highlights the use of continuous flow temporary and durable mechanical circulatory support devices in the ACHD population.
102.
Kim JL, Vaikunth SS, Haeffele C, MacArthur JW. Extracorporeal membrane oxygenator as a bridge to heart–liver en bloc transplant in a patient with Fontan circulation. JTCVS Tech. 2022;12:171–4.PubMedPubMedCentralCrossRef
103.
Belani K, Moreno-Duarte I, White CW, Schroder JN, McCartney SL. Impella placement in a patient with d-transposition of the great arteries after mustard procedure. J Cardiothorac Vasc Anesth. 2020;34(10):2731–5.PubMedCrossRef
104.
Bravo-Jaimes K, Venkatesh P, Lluri G, Reardon L, Cruz D, Vucicevic D, et al. Temporary axial-flow mechanical circulatory support and intravenous treprostinil in a patient with D-transposition of the great arteries and atrial switch: a case report. Int J Cardiol Congenit Heart Dis. 2022;8:100361.CrossRef
105.
Zhou AL, Menachem JN, Danford DA, Kutty S, Cedars AM. UNOS listing status-related changes in mechanical circulatory support utilization and outcomes in adult congenital heart disease patients. J Heart Lung Transplant. 2022;41(7):889–95.PubMedCrossRef
106.
Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, et al. The 2023 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: a 10- year update. J Heart Lung Transplant. 2023:S1053249822022483.
107.
Van De Bruaene A, Toh N, Hickey EJ, Benson L, Horlick E, Granton JT, et al. Pulmonary hypertension in patients with a subaortic right ventricle: prevalence, impact and management. Heart. 2019;105(19):1471–8.PubMedCrossRef
108.
Miranda WR, Jain CC, Connolly HM, DuBrock HM, Cetta F, Egbe AC, et al. Prevalence of pulmonary hypertension in adults after atrial switch and role of ventricular filling pressures. Heart. 2021;107(6):468–73.CrossRef
109.
Zijlstra WM, Elmasry O, Pepplinkhuizen S, Ivy DD, Bonnet D, Luijendijk P, et al. Pulmonary arterial hypertension in children after neonatal arterial switch operation. Heart. 2017;103(16):1244–9.PubMedCrossRef
110.••
Roche SL, Crossland DS, Adachi I, Broda C, Jansen K, Hickey E. Mechanical circulatory support for the failing sub-aortic right ventricle in adults. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2021;24:2–9. This multi-center case series highlights the largest published experience of mechanical circulatory support in the systemic right ventricle.PubMedCrossRef
111.
Saef J, Montgomery R, Cedars A, Tang WHW, Rossano JW, Maeda K, et al. Durable mechanical circulatory support in adult congenital heart disease: reviewing clinical considerations and experience. JCM. 2022;11(11):3200.PubMedPubMedCentralCrossRef
112.
Cedars AM, Schumacher K, Kindel S, Lorts A, Rosenthal D, Chen S, et al. The Fontan VAD physiology project (FVPP). J Heart Lung Transplant. 2020;39(4):S12–3.CrossRef
113.••
Fahnhorst SE, Brandewie K, Perry T, Opotowsky AR, Lubert AM, Lorts A, et al. Single center experience with durable continuous flow single ventricle assist device: a viable option in Fontan circulatory failure. ASAIO J. 2023; https://​doi.​org/​10.​1097/​MAT.​0000000000001986​. This single center case series from Cincinatti Children’s Hospital highlights their experience with the durable mechanical circulatory support (primarily HeartMate 3) in patients with Fontan circulation.
114.
Menachem JN, Schlendorf KH, Mazurek JA, Bichell DP, Brinkley DM, Frischhertz BP, et al. Advanced heart failure in adults with congenital heart disease. JACC Heart Fail. 2020;8(2):87–99.PubMedCrossRef
115.
Givertz MM, DeFilippis EM, Landzberg MJ, Pinney SP, Woods RK, Valente AM. Advanced heart failure therapies for adults with congenital heart disease. J Am Coll Cardiol. 2019;74(18):2295–312.PubMedCrossRef
116.
Huntley GD, Danford DA, Menachem J, Kutty S, Cedars AM. Donor characteristics and recipient outcomes after heart transplantation in adult congenital heart disease. JAHA. 2021;10(14):e020248.PubMedPubMedCentralCrossRef
117.
Jani M, Cook S, Huang SH, Boeve T, Leacche M, Manandhar-Shrestha NK, et al. Increased frequency of heart transplantation, shortened waitlist time and preserved post-transplant survival in adults with congenital heart disease, on the new heart transplant allocation system. Clin Transplant. 2021;35(4) https://​doi.​org/​10.​1111/​ctr.​14205.
118.
Bravo-Jaimes K, Axsom K, Menachem J, Danford D, Kutty S, Cedars A. Impact of the new UNOS donor heart allocation system on waitlist outcomes and early posttransplant mortality among adults with congenital heart disease. Am J Transplant. 2022;22(4):1123–32.PubMedCrossRef
119.
Rali AS, Ranka S, Mazurek JA, Brinkley MD, Cedars A, Clark D, et al. Exception-status listing: a critical pathway to heart transplantation for adults with congenital heart diseases. J Card Fail. 2022;28(3):415–21.PubMedCrossRef
120.
Broda CR, Alonso-Gonzalez R, Ghanekar A, Gulamhusein A, McDonald M, Luk A, et al. Fate of the liver in the survivors of adult heart transplant for a failing Fontan circulation. J Heart Lung Transplant. 2022;41(3):283–6.PubMedCrossRef
121.
D’Souza BA, Fuller S, Gleason LP, Hornsby N, Wald J, Krok K, et al. Single-center outcomes of combined heart and liver transplantation in the failing Fontan. Clin Transplant. 2017;31(3):e12892.CrossRef
122.
123.
Reardon LC, Lin JP, VanArsdell GS, Kaldas FM, Lluri G, Tan W, et al. Orthotopic heart and combined heart liver transplantation: the ultimate treatment option for failing Fontan physiology. Curr Transpl Rep. 2021;8(1):9–20.PubMedCrossRef
124.
Sganga D, Hollander SA, Vaikunth S, Haeffele C, Bensen R, Navaratnam M, et al. Comparison of combined heart–liver vs heart-only transplantation in pediatric and young adult Fontan recipients. J Heart Lung Transplant. 2021;40(4):298–306.PubMedCrossRef
125.••
Lewis MJ, Reardon LC, Aboulhosn J, Haeffele C, Chen S, Kim Y, et al. Clinical outcomes of adult Fontan-associated liver disease and combined heart-liver transplantation. J Am Coll Cardiol. 2023;81(22):2149–60. This multicenter study of 131 adolescent and adult patients (by far the largest sample size published) with Fontan circulation who underwent heart only transplant or combined heart and liver transplant showed improved survival in those who underwent combined organ transplant (86% to 52%) at 5 years post-transplant.PubMedCrossRef
126.
Ortega-Legaspi JM, Hoteit M, Wald J. Immune benefit of combined heart and liver transplantation. Curr Opin Organ Transplant. 2020;25(5):513–8.PubMedCrossRef
127.
Shahandeh N, Kim JS, Tehrani D, Hsu JJ, Nsair A, Khush K, et al. (195) Comparison of CAV development in simultaneous multi-organ and isolated heart transplant recipients in the United States. J Heart Lung Transplant. 2023;42(4):S96.CrossRef
Metadaten
Titel
Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices
verfasst von
Sumeet Vaikunth
Swethika Sundaravel
Joshua Saef
Juan Ortega-Legaspi
Publikationsdatum
16.08.2023
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 5/2023
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-023-00621-1

Weitere Artikel der Ausgabe 5/2023

Current Heart Failure Reports 5/2023 Zur Ausgabe

ReviewPaper

Perspectives on Secondary Mitral Regurgitation in Heart Failure

ReviewPaper

Heart Failure-Related Iron Deficiency Anemia Pathophysiology and Laboratory Diagnosis

ReviewPaper

Telemedicine: an Effective and Low-Cost Lesson From the COVID-19 Pandemic for the Management of Heart Failure Patients

ReviewPaper

Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure

ReviewPaper

Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies

ReviewPaper

Coordinated Metabolic Responses Facilitate Cardiac Growth in Pregnancy and Exercise

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise